Introduction to role:Are you ready to turn complex, multimodal data into decisive actions that shape the future of oncology? This role leads a connected evidence strategy spanning R&D through patient care, where your decisions influence trials, filings, and access strategies that reach patients faster. You will help power an enterprise-scale AI and data engine by being an exceptional connector leveraging existing capabilities, scaling what works, and exporting breakthrough ideas across teams and geographies.
Can you see yourself guiding senior stakeholders through complex trade-offs to deliver impact at scale? You will own the end-to-end evidence agenda for an oncology therapeutic area, aligning it to the highest-priority scientific, medical, and business needs across the lifecycle. By harnessing the PH3ID Intelligence Foundation and rich multimodal assets, you will translate signals into intelligence that advances portfolio investment decisions, strengthens regulatory packages, and sharpens commercial positioning.
You will work at the interface of Translational Science, Clinical Development, and Market Access leading without direct authority in a matrixed environment. Join a team dedicated to building AI-enabled evidence that persists and extends across use cases, helping a fast-growing therapeutic area set the pace for the portfolio.
Accountabilities: End-to-End Evidence Strategy: Own the clinical intelligence and real-world evidence strategy from R&D through patient care, building a clear roadmap tied to the most critical scientific, medical, and business priorities across development, regulatory, and market access.
Evidence Gap Prioritization: Define and rank the evidence gaps that matter most, informing PH3ID, trial design, external control arm strategies, and subpopulation discovery to accelerate confident decisions.
Translational and Clinical Partnership: Partner with Translational Science and Clinical Development to integrate genomics, imaging, digital endpoints, and pathology AI into strategies for patient stratification and biomarker-driven development.
AI-Enabled Hematology Methods: Advance AI-driven approaches including tumor dynamics forecasting, prognostic risk adjustment, trial simulation, and transportability analyses to de-risk and optimize clinical programs.
Integrated Insight Generation: Convert internal and competitor trial data, together with real-world data, into actionable insight on standard of care, patient journeys, unmet need, and competitive positioning that guides development and access strategies.
Stakeholder Influence and Alignment: Influence Global Product Teams, matrix partners, and external data collaborators to ensure evidence outputs are both methodologically rigorous and strategically relevant.
Compounding Intelligence Foundation: Build an oncology therapeutic area specific intelligence that persists and grows within the PH3ID Intelligence Foundation so evidence compounds across use cases rather than being rebuilt each time.
Immediate Broader Impact: Deliver early wins that inform ongoing trials and filings, then scale reusable capabilities and standards that elevate decision quality across the hematology portfolio.
Essential Skills/Experience: Leadership & Influence
- Track record of translating complex analytical outputs into strategic recommendations that advise portfolio decisions.
- Experience working at the interface of Translational Science, Clinical Development, and Market Access functions, with the ability to distill technical complexity into clear narratives for diverse audiences.
- Demonstrated ability to lead without authority, influencing senior collaborators and cross-functional teams in a matrixed environment.
Technical and Strategic Expertise
- Expert command of oncology real-world data assets and their application to evidence generation.
- Proven track record to build end-to-end evidence strategies that address both clinical development needs (trial design, regulatory submissions) and market access needs (HTA requirements, payer value narratives).
- Strong foundation in evidence generation methodologies, including observational study design, causal inference, comparative effectiveness research, and external control arms.
- Experience with regulatory submissions or HTA dossiers leveraging RWE.
- Solid understanding of multimodal modeling approaches, and how clinical, imaging, genomic, and real-world data can be integrated to build patient classifiers, prognostic models, and trial simulators.
Education and Experience - Advanced degree (PhD, PharmD, MD, or equivalent) in epidemiology, biostatistics, health economics, clinical science, or a quantitative discipline relevant to evidence generation.
- 7+ years of experience in evidence generation, RWE, health outcomes research, or a related function within pharma, biotech, or a leading academic or consultancy environment.
Desirable Skills/Experience: - Familiarity with AI/ML applications in RWE, including predictive modeling and automated evidence synthesis.
- Prior experience shaping or contributing to AI-enabled evidence platforms.
In-Office Working Requirements When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working gives us the platform we need to connect, work at pace and challenge perceptions. That's why we work, on average, a minimum of three days per week from the office. But that doesn't mean we're not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.
The annual base pay for this position ranges from $ 186.014,40 to $279.021,60. Our positions offer eligibility for various incentives-an opportunity to receive short-term incentive bonuses, equity-based awards for salaried roles and commissions for sales roles. Benefits offered include qualified retirement programs, paid time off (i.e., vacation, holiday, and leaves), as well as health, dental, and vision coverage in accordance with the terms of the applicable plans.
Ready to make a difference? Apply now!
Call to Action:
Step into a role where your evidence strategy will shape portfolio bets, strengthen regulatory confidence, and open access for patients-make your next move count.
Date Posted11-sep.-2026
Closing Date25-sep.-2026
